Structure Therapeutics Inc. - 8-K Filing
Structure Therapeutics reports Q3 2026 net loss of $144.8 million and maintains $1.2 billion cash position to fund operations through 2028. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $GPCR